THEORETICAL ASPECTS IN THE FORMATION OF
PEDAGOGICAL SCIENCES
International scientific-online conference
124
INSULIN AND ITS ROLE IN DIABETES MELLITUS
Irkinjanova Fayzixon
University of Business and Science, Department of Therapeutic Work
24_05 group students
Sobirov Olimjon Odiljonovich
Scientific advisor:
https://doi.org/10.5281/zenodo.15488653
Abstract:
Diabetes mellitus, a global health crisis characterized by chronic
hyperglycemia, affects over 500 million individuals, driving significant
morbidity and mortality. Insulin, a peptide hormone secreted by pancreatic beta
cells, is pivotal in regulating glucose homeostasis and managing diabetes. This
article provides an exhaustive exploration of insulin’s biochemical structure,
molecular mechanisms, and therapeutic applications in type 1 and type 2
diabetes. It examines insulin’s biosynthesis, signaling pathways, and the
pathophysiology of insulin deficiency and resistance, while highlighting cutting-
edge advancements in insulin therapy, including recombinant analogs, smart
delivery systems, and regenerative approaches. Challenges such as
hypoglycemia, weight gain, patient adherence, and global access disparities are
critically analyzed. By synthesizing contemporary scientific evidence, this article
underscores insulin’s indispensable role in mitigating diabetic complications,
enhancing quality of life, and addressing the escalating diabetes epidemic.
Keywords:
Insulin, diabetes mellitus, glucose homeostasis, insulin
resistance, insulin therapy, hyperglycemia, beta cells, recombinant insulin, type
1 diabetes, type 2 diabetes, continuous glucose monitoring, insulin analogs.
Diabetes mellitus, encompassing type 1 and type 2 forms, stands as a
formidable global health challenge, with prevalence surpassing 500 million
cases and projections estimating further escalation by 2045. Defined by
persistent hyperglycemia, diabetes results from impaired insulin production,
action, or both, leading to devastating complications including cardiovascular
disease, diabetic retinopathy, nephropathy, neuropathy, and lower-limb
amputations. The discovery of insulin in 1921 by Frederick Banting and Charles
Best marked a transformative milestone, converting a once-lethal condition into
a manageable chronic disease. Insulin, a 51-amino-acid peptide hormone,
orchestrates glucose, lipid, and protein metabolism, serving as the linchpin of
metabolic homeostasis. Its role extends beyond glycemic control to influence
cellular growth, differentiation, and energy storage, making it indispensable in
both physiological and pathological contexts. This article offers an in-depth
examination of insulin’s biochemical properties, physiological mechanisms, and
THEORETICAL ASPECTS IN THE FORMATION OF
PEDAGOGICAL SCIENCES
International scientific-online conference
125
therapeutic significance in diabetes management, emphasizing its critical role in
type 1 and type 2 diabetes, while addressing current challenges and future
directions in insulin-based therapies. By integrating molecular insights, clinical
advancements, and public health perspectives, it aims to elucidate insulin’s
enduring importance in combating the diabetes epidemic.
Insulin is encoded by the INS gene on chromosome 11 and synthesized in
pancreatic beta cells within the islets of Langerhans. The biosynthetic pathway
begins with preproinsulin, a 110-amino-acid precursor, which is cleaved in the
endoplasmic reticulum to yield proinsulin. Subsequent enzymatic processing by
prohormone convertases (PC1/3 and PC2) and carboxypeptidase E in the Golgi
apparatus produces mature insulin, comprising A (21 amino acids) and B (30
amino acids) chains linked by two disulfide bonds, with an intrachain disulfide
bond stabilizing the A chain. Insulin secretion is a tightly regulated process
triggered by glucose metabolism. Glucose enters beta cells via GLUT2
transporters, undergoes glycolysis and oxidative phosphorylation, and increases
the ATP/ADP ratio. This closes ATP-sensitive potassium channels (KATP),
depolarizing the beta-cell membrane and opening voltage-gated calcium
channels. The resultant calcium influx stimulates insulin granule exocytosis.
Other stimuli, including amino acids, incretin hormones (e.g., GLP-1), and vagal
nerve activation, amplify insulin release, ensuring precise glycemic control.
Upon secretion, insulin exerts its effects by binding to the insulin receptor, a
transmembrane tyrosine kinase. Receptor autophosphorylation activates
downstream cascades, primarily the phosphatidylinositol 3-kinase (PI3K)-Akt
pathway, which promotes glucose transporter 4 (GLUT4) translocation to the
plasma membrane in skeletal muscle and adipose tissue, facilitating glucose
uptake. Simultaneously, insulin inhibits hepatic gluconeogenesis and
glycogenolysis by suppressing key enzymes (e.g., PEPCK, G6Pase) and promotes
glycogenesis and lipogenesis via activation of glycogen synthase and acetyl-CoA
carboxylase, respectively. In non-classical tissues, such as the brain and
endothelium, insulin modulates neuroprotection and vascular function,
highlighting its pleiotropic roles. Dysregulation of these processes underpins
diabetes pathophysiology.
Type 1 diabetes, affecting 5-10% of diabetic patients, results from
autoimmune destruction of beta cells, mediated by T-cell infiltration and
autoantibodies targeting glutamic acid decarboxylase (GAD65), insulin, and islet
antigen-2 (IA-2). Genetic predispositions (e.g., HLA-DR3/DR4 haplotypes) and
environmental triggers, such as coxsackievirus infections, contribute to beta-cell
THEORETICAL ASPECTS IN THE FORMATION OF
PEDAGOGICAL SCIENCES
International scientific-online conference
126
loss, leading to absolute insulin deficiency. Patients develop severe
hyperglycemia, weight loss, and diabetic ketoacidosis (DKA), a life-threatening
condition characterized by ketone accumulation and acidosis. Lifelong
exogenous insulin therapy is essential to prevent DKA and maintain metabolic
stability. In contrast, type 2 diabetes, comprising 90-95% of cases, is driven by
insulin resistance, where target tissues exhibit diminished responsiveness to
insulin, often compounded by progressive beta-cell dysfunction. Insulin
resistance is multifactorial, involving visceral obesity, chronic inflammation, and
genetic variants (e.g., TCF7L2 polymorphisms). Elevated free fatty acids, TNF-α,
IL-6, and resistin impair insulin signaling by inducing serine phosphorylation of
insulin receptor substrate-1 (IRS-1), disrupting PI3K-Akt activation. Initially,
beta cells compensate with hyperinsulinemia, but chronic glucolipotoxicity and
endoplasmic reticulum stress precipitate beta-cell apoptosis, reducing insulin
secretion and exacerbating hyperglycemia.
Insulin therapy is the cornerstone of type 1 diabetes management and a
critical intervention in advanced type 2 diabetes. The development of
recombinant human insulin in the 1980s, using Escherichia coli and yeast
expression systems, eliminated reliance on animal-derived insulin, reducing
immunogenicity and improving supply. Insulin analogs, engineered through
amino acid substitutions, mimic physiological insulin profiles more effectively.
Rapid-acting analogs (e.g., lispro, aspart, glulisine) exhibit faster onset and
shorter duration, ideal for postprandial glucose control, while long-acting
analogs (e.g., glargine, detemir, degludec) provide stable basal insulin levels,
minimizing nocturnal hypoglycemia. Delivery systems have evolved
significantly, with insulin pens offering dosing precision and portability, and
insulin pumps enabling continuous subcutaneous insulin infusion (CSII) with
programmable basal and bolus doses. Continuous glucose monitoring (CGM)
systems, integrated with pumps in hybrid closed-loop systems, adjust insulin
delivery in real-time based on interstitial glucose levels, achieving HbA1c
reductions of 0.5-1.0% and reducing hypoglycemic events by up to 40%.
Emerging technologies, such as fully closed-loop systems and implantable
insulin reservoirs, promise further precision, approximating an “artificial
pancreas.”
Despite these advancements, insulin therapy faces substantial challenges.
Hypoglycemia, affecting 20-30% of insulin-treated patients annually, arises from
mismatches between insulin doses and glucose availability, particularly during
exercise, fasting, or medication errors. Severe hypoglycemia can cause seizures,
THEORETICAL ASPECTS IN THE FORMATION OF
PEDAGOGICAL SCIENCES
International scientific-online conference
127
coma, or death, necessitating patient education on carbohydrate counting and
glucagon use. Weight gain, reported in 50-70% of patients initiating insulin,
stems from insulin’s anabolic effects, reduced glycosuria, and compensatory
hyperphagia to prevent hypoglycemia, complicating management in type 2
diabetes, where obesity is prevalent. Injection-related discomfort, needle
phobia, and complex regimens deter adherence, with studies indicating that 20-
30% of patients skip doses, increasing HbA1c by 0.3-0.8%. Socioeconomic
barriers, including insulin costs (ranging from $100-300/month in high-income
countries) and supply chain disruptions in low-income regions, exacerbate
disparities, with 50% of patients in sub-Saharan Africa lacking consistent access.
Cultural stigma and inadequate diabetes education further hinder optimal
therapy, particularly in rural settings.
Innovative research is addressing these challenges. Beta-cell regeneration,
using induced pluripotent stem cells (iPSCs) or small-molecule agonists of beta-
cell transcription factors (e.g., PDX1, MafA), aims to restore endogenous insulin
production in type 1 diabetes. Encapsulation technologies protect transplanted
beta cells from immune attack, with clinical trials reporting sustained insulin
independence for up to 12 months. In type 2 diabetes, novel insulin-sensitizing
agents, such as PPARγ modulators and AMPK activators, enhance insulin
signaling, reducing exogenous insulin requirements. Gene therapy, including
CRISPR/Cas9-mediated correction of INS gene mutations or IRS-1
overexpression, offers potential for long-term metabolic correction.
Pharmacogenomics is transforming insulin therapy by identifying genetic
markers (e.g., KCNJ11 variants) that predict responsiveness to specific analogs,
enabling personalized regimens. For example, patients with ABCC8 mutations
may benefit from sulfonylureas over insulin, highlighting the value of genetic
profiling.
Public health strategies are critical for addressing insulin resistance, the
primary driver of type 2 diabetes. Obesity, affecting 650 million adults globally,
increases visceral fat, which secretes adipokines (e.g., leptin, adiponectin) that
impair insulin signaling. Sedentary behavior and high-glycemic diets exacerbate
insulin resistance by elevating postprandial glucose and lipid levels. Structured
lifestyle interventions, including 150 minutes/week of moderate aerobic
exercise and low-carbohydrate diets, improve insulin sensitivity by 20-30%,
reducing HbA1c by 0.5-1.0%. Community-based programs, such as diabetes
prevention initiatives in Uzbekistan, integrate dietary counseling, physical
activity promotion, and insulin access to curb disease progression. Digital health
THEORETICAL ASPECTS IN THE FORMATION OF
PEDAGOGICAL SCIENCES
International scientific-online conference
128
tools, including mobile apps for glucose tracking and telemedicine platforms,
enhance patient engagement, with studies reporting 15-20% improvements in
adherence.
The economic and societal burden of diabetes, costing $1.3 trillion annually,
underscores insulin’s pivotal role. By normalizing glycemia, insulin prevents
microvascular complications, reducing retinopathy incidence by 60% and
nephropathy progression by 50%. Macrovascular benefits, including 20-30%
reductions in myocardial infarction risk, are achieved through intensive insulin
therapy, particularly when initiated early. However, achieving these outcomes
requires addressing systemic barriers. In Uzbekistan, where diabetes prevalence
exceeds 7%, limited healthcare infrastructure and insulin affordability challenge
care delivery. Multidisciplinary care models, involving endocrinologists,
dietitians, and community health workers, are essential for patient
empowerment. Policy interventions, such as insulin price caps and WHO’s Global
Diabetes Compact, aim to ensure universal access, targeting a 50% reduction in
insulin-related mortality by 2030.
In conclusion, insulin’s discovery heralded a new era in diabetes care, and
its role remains unparalleled in managing hyperglycemia and preventing
complications. From its intricate biosynthesis in beta cells to its sophisticated
therapeutic applications, insulin embodies the synergy of molecular biology,
pharmacology, and clinical innovation. Its ability to restore metabolic balance in
type 1 diabetes and augment control in type 2 diabetes is transformative, yet
challenges—hypoglycemia, weight gain, adherence, and access—persist. Next-
generation analogs, smart delivery systems, and regenerative therapies are
poised to enhance insulin’s efficacy, while preventive strategies targeting insulin
resistance through lifestyle modification are vital for curbing the diabetes
epidemic. As global prevalence escalates, insulin’s legacy as a therapeutic
cornerstone endures, necessitating sustained scientific, clinical, and policy
efforts to optimize its application, improve patient outcomes, and ensure
equitable access. In Uzbekistan and beyond, insulin remains a beacon of hope,
bridging the gap between scientific discovery and human health in the fight
against diabetes.
References:
1. Karimov, A. A., & Saidova, F. M. (2020). Diabetes: Pathogenesis and Modern
Approaches to Treatment. Tashkent: Medical Publishing House.
2. Murodov, B. Kh. (2018). The Role of Insulin Therapy in Endocrinology.
Samarkand: Samarkand State Medical Institute.
THEORETICAL ASPECTS IN THE FORMATION OF
PEDAGOGICAL SCIENCES
International scientific-online conference
129
3. Toshpulatova, N. R. (2022). Insulin Resistance and Its Molecular Basis in
Diabetes. Tashkent: Uzbekistan Medical Journal.
